Corporate Banner
Satellite Banner
Technology Networks Header
Friday, October 24, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Bio-Rad Droplet Digital™ PCR and Organ Transplant Rejection
  Videos

Return

Bio-Rad Droplet Digital™ PCR and Organ Transplant Rejection
Bio-Rad Laboratories

Researchers at Chronix Biomedical applied Bio-Rad's ddPCR™ technology to quantify graft-derived cell-free DNA (cfDNA) in recent liver transplant patients and in stable patients who had undergone a transplant procedure more than six months earlier. ddPCR technology allowed Chronix to develop a fast and cost-effective laboratory test to detect cfDNA released into the blood stream by dying cells from the transplanted organ.

Sequencing methods typically require batch sampling, but using ddPCR assays, researchers are able to run single samples. Additionally, this method reduces test time from three days or more to one day, and reduces costs by 90 percent. The study authors were able to address the need for donor DNA by preselecting single-nucleotide polymorphisms (SNPs) that ensure enough heterogeneity between donor and recipient. The new blood test can also deliver results up to several days earlier than the conventional aspartate aminotransferase (AST) and bilirubin tests for liver transplantation rejection, with the potential for an immediate positive impact on patient care.

Chronix Biomedical is a molecular diagnostics company developing blood tests primarily for cancer, including companion diagnostics and tests for detecting minimal residual disease. Chronix is preparing to offer its pioneering tests through its own laboratories under CLIA certification in North America and the CE mark in Europe. The Company's initial product is a test to be used by cancer treatment centers and oncologists in the treatment of breast cancer patients. Chronix is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany and Brookings, South Dakota.

The Droplet Digital PCR system enables the quantification of target DNA with unrivaled precision by partitioning samples into 20,000 nanoliter-sized droplets. After PCR on a thermal cycler, PCR-positive and PCR-negative droplets are counted to provide absolute quantification of the target DNA. The QX200™ system, Bio-Rad's second-generation digital PCR system, provides absolute quantification of target DNA or RNA molecules using EvaGreen or TaqMan hydrolysis probes, yielding unmatched sensitivity and precision for a wide variety of applications.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
IDT Shares Tips for Optimizing Target Capture
The article discusses improved target capture methods for increasing reliability of next generation sequencing data.
CDC Develops a New, Faster Lab Test for Enterovirus D68
Confirmed cases will appear to rise as agency accelerates specimen testing.
New 'Lab-on-a-Chip' Could Revolutionize Early Diagnosis of Cancer
Faster result times, reduced costs, minimal sample demands and better sensitivity of analysis.
NanoString, Brigham and Women’s Hospital Collaborate
Research collaboration to accelerate translation of genomic discoveries into clinical diagnostics in oncology.
Biologists Find An Early Sign Of Cancer
Patients show boost in certain amino acids years before diagnosis of pancreatic cancer.
New DNA Sequencing Method to Diagnose Tuberculosis
Teams aim to test the metagenomics technique on a wide range of samples.
Inivata Raises £4m to Realize the Potential of ctDNA Analysis
New spin-out from Cancer Research UK launched with funding from Imperial Innovations, Cambridge Innovation Capital and Johnson & Johnson Development Corporation.
Blood Test May Help Determine Psychosis Risk
A study led by University of North Carolina at Chapel Hill researchers represents an important step forward in the accurate diagnosis of people who are experiencing the earliest stages of psychosis.
Asuragen’s Xpansion Interpreter® Test Study of 1,040 Transmissions of Fragile X Alleles
Study reveals personalized risks for expansion from parent to child.
Blood Test To Diagnose Depression
Test identifies nine blood markers tied to depression; predicts who will benefit from therapy.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv